N@N

GAITHERSBURG, Md.--([ BUSINESS WIRE ])--AccelPath, Inc. (OTCBB: ACLP) (aAccelPatha or the aCompanya) announced today that Professor Mahadev Satyanarayanan, Ph.D. (aProfessor Satyaa) continues his role as an active member of the Companyas Medical Advisory Board.

"We are very pleased with our continuing collaborative relationship with Satya"

Professor Satya is the Carnegie Group Professor of Computer Science at Carnegie Mellon University. He received his Ph.D., Computer Science from Carnegie Mellon and his Bachelor's and Master's degrees from the Indian Institute of Technology, Madras. From May 2001 to May 2004, Professor Satya served as the founding director of[ Intel Research Pittsburgh ], one of four university-affiliated research labs established worldwide by Intel to create disruptive information technologies through its Open Collaborative Research model. He is a Fellow of the ACM and the IEEE, and was the founding Editor-in-Chief of[ IEEE Pervasive Computing ].

As an experimental computer scientist, Satya designs, implements, and evaluates systems. His research interests span mobile computing, pervasive computing and distributed systems (especially distributed file systems). Performance, availability, security, usability and manageability are some of the key attributes that he pays attention to in his work.

Professor Satya has developed expertise in deep search of non-text data such as digital photographs and medical images. This has led to OpenSlide, a vendor-neutral open-source library for whole-slide images in digital pathology and OpenDP.org, an open source eco-system for digital pathology.

Another outcome of Satyaas studies is the Coda File System, which supports disconnected and bandwidth-adaptive operation. Key ideas from Coda have been incorporated by Microsoft into the IntelliMirrorcomponent of Windows. An additional outcome is Odyssey, a set of open-source operating system extensions for enabling mobile applications to adapt to variation in critical resources such as bandwidth and energy. Coda and Odyssey are building blocks in Project Aura, a research initiative at Carnegie Mellon to build a distraction-free ubiquitous computing environment.

Early in his career, Satya was a principal architect and implementor of the Andrew File System (AFS) which pioneered the use of scalable file caching, ACL-based security, and volume-based system administration for enterprise-scale information sharing. AFS was [ commercialized by IBM ], is in widespread use today as [ OpenAFS ], and has heavily influenced the [ NFS v4 ] network file system protocol standard that was published in April 2003. AFS was commercialized by IBM.

aAfter working this past year with AccelPathas management and board members, I am pleased to continue assisting the Company as part of the Medical Advisory Board,a stated Professor Satya. aThe Company is on an exciting road of implementing digital telepathology networks in the US and abroad. Specifically, I will continue to assist the Company with developing its digital pathology solution and, in conjunction, establishing a proprietary, searchable database of pathology cases that can ultimately be accessed by the industry as a reference tool to assist with difficult cases.a

aWe are very pleased with our continuing collaborative relationship with Satya,a stated Shekhar Wadekar, AccelPathas Chairman and Chief Executive Officer. aSatyaas expertise in deep search of non-text data such as digital photographs and medical images has led to OpenSlide, a vendor-neutral open-source library for whole-slide images in digital pathology and OpenDP.org, an open source eco-system for digital pathology. His expertise provides us significant insights while we enhance our proprietary digital telepathology solutions. He will also be invaluable as we further apply those to existing pathology laboratories and related service providers.a

About AccelPath

AccelPath provides technology solutions that play a key role in delivering information required for diagnosis of diseases and other pathologic conditions with and through its associated institutional pathologists. The medical institutions, with whom the Company partners, prepare comprehensive diagnostic reports of a patientas condition and consult with referring physicians to help determine the most appropriate treatment. Such diagnostic reports enable the early detection of disease, allowing referring physicians to make informed and timely treatment decisions that improve their patientsa health in a cost-effective manner. The Company seeks out referring physicians and histology laboratories in need of high-quality pathology interpretations and manages HIPAA-compliant digital case delivery and reporting while developing comprehensive solutions for managing medical information.

AccelPath is currently focused on the $14 billion anatomic pathology market in the US. The Companyas business model builds upon the expertise of experienced pathologists to provide seamless, reliable and comprehensive pathology and special test offerings to referring physicians using conventional and digital technologies.The Company establishes longstanding relationships with the referring physicians as a result of focused delivery of its partneras diagnostic services, personalized responses and frequent consultations, and its proprietary flexible information technology, or IT, solutions that are customizable to the referring physiciansa or laboratories as well as the pathologistsa needs. Such diagnostic reports often enable the early detection of disease, allowing referring physicians to make informed and timely treatment decisions that improve their patientsa health in a cost-effective manner. AccelPathas IT and communications platform enables it to efficiently and securely deliver diagnostic reports to referring physicians. In addition, AccelPathas IT platform enables close tracking and monitoring of medical statistics.

AccelPath is focused on the design, research, development and integration of three-dimensional imaging devices and systems primarily in the healthcare industries which it contributes to the Company. The Company will also exploit its three-dimensional imaging technology for use in intelligent surveillance devices and systems, as well as three-dimensional facial recognition systems for security and law enforcement agencies thru future strategic partnerships. Historically, the Companyas largest customers have been the National Institutes of Health and the Department of Defense.

Additional Company information may be found on the Internet at: [ www.accelpath.com ].

Forward-Looking Statements

This press release contains certain aforward-looking statementsa relating to the business of the Company, which can be identified by the use of forward-looking terminology such as amay,a awill,a aexpect,a aanticipate,a aintend,a aestimate,a abelieve,a aproject,a acontinue,a aplan,a aforecast,a or other similar words, or the negative thereof, unless the context requires otherwise. These statements include, but are not limited to, statements about the Companyas current discussions with scanner manufacturers, the Companyas expected future performance and the acceptance of the Companyas product offerings. The results anticipated by any or all of these forward-looking statements may not occur. In addition, these statements reflect managementas current views with respect to future events and are subject to numerous risks, uncertainties and other factors that could cause actual results to differ materially from those set forth in or implied by these forward-looking statements. Factors that could affect those results include, but are not limited to, our ability to conclude our discussions with these manufacturers on favorable terms, the acceptance of our solutions in the marketplace, the efforts of our sales force, general economic conditions, and those described in the Companyas reports on Forms 8-K, 10-Q and 10-K and proxy statements and information statements including amendments, which have been or will be filed by the Company with the Securities and Exchange Commission (the aSECa), including without limitation under the caption aRisk Factorsa in the Company's Annual Report on Form 10-K filed on October 13, 2011. Many of the factors that will determine the outcome of the subject matter of this press release are beyond the Companyas ability to control or predict. The Company undertakes no obligation and expressly disclaim any obligation, to revise or publicly update any forward-looking statements, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.